Targeting myeloid-derived suppressor cells for cancer immunotherapy Yijun LiuGuowei WeiHong Qin Review 31 May 2018 Pages: 1181 - 1195
Occurrence of type 1 and type 2 diabetes in patients treated with immunotherapy (anti-PD-1 and/or anti-CTLA-4) for metastatic melanoma: a retrospective study Marie-Léa GauciPhilippe BoudouJean-François Gautier Original Article 28 May 2018 Pages: 1197 - 1208
Merkel cell carcinoma and cellular cytotoxicity: sensitivity to cellular lysis and screening for potential target antigens suitable for antibody-dependent cellular cytotoxicity Jocelyn OllierThibault KervarrecBéatrice Clémenceau Original Article 28 May 2018 Pages: 1209 - 1219
Establishment of adoptive cell therapy with tumor infiltrating lymphocytes for non-small cell lung cancer patients Ronny Ben-AviRonit FarhiMichal J. Besser Original Article 29 May 2018 Pages: 1221 - 1230
Randomized controlled phase III trial of adjuvant chemoimmunotherapy with activated cytotoxic T cells and dendritic cells from regional lymph nodes of patients with lung cancer Hideki KimuraYukiko MatsuiToshihiko Iizasa Original Article Open access 31 May 2018 Pages: 1231 - 1238
Differential regulation of human monocytes and NK cells by antibody-opsonized tumors Jun YinAlex J. AlbersJohn O. Richards Original Article 31 May 2018 Pages: 1239 - 1250
Bispecific light T-cell engagers for gene-based immunotherapy of epidermal growth factor receptor (EGFR)-positive malignancies Kasper MølgaardSeandean L. HarwoodLuis Alvarez-Vallina Original Article 04 June 2018 Pages: 1251 - 1260
Longitudinal studies of the 18F-FDG kinetics after ipilimumab treatment in metastatic melanoma patients based on dynamic FDG PET/CT Christos SachpekidisHoda AnwarAntonia Dimitrakopoulou-Strauss Original Article 05 June 2018 Pages: 1261 - 1270
Inhibition of the adenosine A2a receptor modulates expression of T cell coinhibitory receptors and improves effector function for enhanced checkpoint blockade and ACT in murine cancer models Robert D. LeoneIm-Meng SunJonathan D. Powell Original Article 19 June 2018 Pages: 1271 - 1284
Antibody-dependent cell-mediated cytotoxicity induced by active immunotherapy based on racotumomab in non-small cell lung cancer patients Valeria I. SegatoriHéctor A. CuelloMariano R. Gabri Original Article 23 June 2018 Pages: 1285 - 1296
Expression of CD3, PD-L1 and CTLA-4 in mammary and extra-mammary Paget disease Georgia KarpathiouCeline ChauleurMichel Peoc’h Original Article 25 June 2018 Pages: 1297 - 1303
Indoleamine 2,3-dioxygenase provides adaptive resistance to immune checkpoint inhibitors in hepatocellular carcinoma Zachary J. BrownSu Jong YuTim F. Greten Original Article 29 June 2018 Pages: 1305 - 1315
Immune checkpoint blockade therapy of mesothelioma: a clinical and radiological challenge Luana CalabròAldo MorraMichele Maio Focussed Research Review 26 June 2018 Pages: 1317 - 1324
Immune-mediated cholangitis: is it always nivolumab’s fault? Francesco GelsominoGiovanni VitaleAndrea Ardizzoni Letter to the Editors 05 April 2018 Pages: 1325 - 1327
Response to “Immune-mediated cholangitis: is it always nivolumab’s fault?” Jumpei KashimaYusuke Okuma Letter to the Editors 26 April 2018 Pages: 1329 - 1330